Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer

Background This phase II study was initiated to determine the efficacy and safety of gemcitabine plus cisplatin in patients with pancreatic cancer. Patients and methods Gemcitabine 1000 mg/m2 was given on days 1, 8, and 15 of a 28-day schedule, and cisplatin 50 mg/m2 on days 1 and 15 to chemonaive p...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of oncology 2000-11, Vol.11 (11), p.1399-1403
Hauptverfasser:	Heinemann, V., Wilke, H., Mergenthaler, H.-G., Clemens, M., König, H., Illiger, H. J., Arning, M., Schalhorn, A., Possinger, K., Fink, U.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Chemotherapy cisplatin Cisplatin - administration & dosage Cisplatin - adverse effects combination chemotherapy Combined Modality Therapy Deoxycytidine - administration & dosage Deoxycytidine - adverse effects Deoxycytidine - analogs & derivatives Female Gastrointestinal Diseases - chemically induced gemcitabine Hematologic Diseases - chemically induced Humans Life Tables Male Medical sciences Middle Aged Neoplasm Metastasis Pancreatectomy pancreatic cancer Pancreatic Neoplasms - drug therapy Pancreatic Neoplasms - mortality Pancreatic Neoplasms - surgery Patient Acceptance of Health Care Pharmacology. Drug treatments prolonged survival Quality of Life Survival Analysis Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!